|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PIP4P1 |
Gene summary for PIP4P1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PIP4P1 | Gene ID | 90809 |
| Gene name | phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1 | |
| Gene Alias | C14orf9 | |
| Cytomap | 14q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006066 | UniProtAcc | Q86T03 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 90809 | PIP4P1 | LZE2T | Human | Esophagus | ESCC | 9.54e-06 | 4.66e-01 | 0.082 |
| 90809 | PIP4P1 | LZE4T | Human | Esophagus | ESCC | 1.20e-04 | 1.72e-01 | 0.0811 |
| 90809 | PIP4P1 | LZE5T | Human | Esophagus | ESCC | 1.54e-04 | 2.80e-01 | 0.0514 |
| 90809 | PIP4P1 | LZE7T | Human | Esophagus | ESCC | 2.56e-05 | 2.13e-01 | 0.0667 |
| 90809 | PIP4P1 | LZE20T | Human | Esophagus | ESCC | 8.11e-14 | 3.71e-01 | 0.0662 |
| 90809 | PIP4P1 | LZE22T | Human | Esophagus | ESCC | 1.57e-03 | 3.08e-01 | 0.068 |
| 90809 | PIP4P1 | LZE24T | Human | Esophagus | ESCC | 1.53e-37 | 7.88e-01 | 0.0596 |
| 90809 | PIP4P1 | LZE21T | Human | Esophagus | ESCC | 1.37e-06 | 3.87e-01 | 0.0655 |
| 90809 | PIP4P1 | S014 | Human | Liver | HCC | 1.09e-29 | 7.40e-01 | 0.2254 |
| 90809 | PIP4P1 | S015 | Human | Liver | HCC | 5.30e-26 | 7.78e-01 | 0.2375 |
| 90809 | PIP4P1 | S016 | Human | Liver | HCC | 1.32e-27 | 6.70e-01 | 0.2243 |
| 90809 | PIP4P1 | S027 | Human | Liver | HCC | 3.80e-02 | 2.77e-01 | 0.2446 |
| 90809 | PIP4P1 | S028 | Human | Liver | HCC | 6.37e-10 | 3.21e-01 | 0.2503 |
| 90809 | PIP4P1 | S029 | Human | Liver | HCC | 1.36e-08 | 3.90e-01 | 0.2581 |
| 90809 | PIP4P1 | male-WTA | Human | Thyroid | PTC | 6.59e-21 | 2.48e-01 | 0.1037 |
| 90809 | PIP4P1 | PTC01 | Human | Thyroid | PTC | 1.13e-11 | 2.65e-01 | 0.1899 |
| 90809 | PIP4P1 | PTC04 | Human | Thyroid | PTC | 5.11e-12 | 2.63e-01 | 0.1927 |
| 90809 | PIP4P1 | PTC05 | Human | Thyroid | PTC | 3.67e-16 | 4.97e-01 | 0.2065 |
| 90809 | PIP4P1 | PTC06 | Human | Thyroid | PTC | 2.88e-31 | 6.35e-01 | 0.2057 |
| 90809 | PIP4P1 | PTC07 | Human | Thyroid | PTC | 1.65e-23 | 4.27e-01 | 0.2044 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000606621 | Liver | HCC | alcohol metabolic process | 208/7958 | 353/18723 | 2.80e-10 | 9.50e-09 | 208 |
| GO:19026522 | Liver | HCC | secondary alcohol metabolic process | 100/7958 | 147/18723 | 3.26e-10 | 1.09e-08 | 100 |
| GO:00082032 | Liver | HCC | cholesterol metabolic process | 94/7958 | 137/18723 | 5.39e-10 | 1.72e-08 | 94 |
| GO:007233122 | Liver | HCC | signal transduction by p53 class mediator | 108/7958 | 163/18723 | 7.14e-10 | 2.23e-08 | 108 |
| GO:00082022 | Liver | HCC | steroid metabolic process | 188/7958 | 319/18723 | 1.96e-09 | 5.63e-08 | 188 |
| GO:00161252 | Liver | HCC | sterol metabolic process | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
| GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
| GO:001631121 | Liver | HCC | dephosphorylation | 230/7958 | 417/18723 | 1.00e-07 | 1.96e-06 | 230 |
| GO:190179622 | Liver | HCC | regulation of signal transduction by p53 class mediator | 64/7958 | 93/18723 | 2.53e-07 | 4.45e-06 | 64 |
| GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
| GO:003025821 | Liver | HCC | lipid modification | 123/7958 | 212/18723 | 3.50e-06 | 4.58e-05 | 123 |
| GO:00069911 | Liver | HCC | response to sterol depletion | 17/7958 | 18/18723 | 5.15e-06 | 6.44e-05 | 17 |
| GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
| GO:00319291 | Liver | HCC | TOR signaling | 78/7958 | 126/18723 | 8.49e-06 | 9.97e-05 | 78 |
| GO:0032006 | Liver | HCC | regulation of TOR signaling | 63/7958 | 104/18723 | 1.50e-04 | 1.20e-03 | 63 |
| GO:0032008 | Liver | HCC | positive regulation of TOR signaling | 31/7958 | 47/18723 | 9.90e-04 | 5.71e-03 | 31 |
| GO:0070071 | Liver | HCC | proton-transporting two-sector ATPase complex assembly | 12/7958 | 15/18723 | 3.56e-03 | 1.59e-02 | 12 |
| GO:1904263 | Liver | HCC | positive regulation of TORC1 signaling | 14/7958 | 20/18723 | 1.21e-02 | 4.41e-02 | 14 |
| GO:0072331113 | Thyroid | PTC | signal transduction by p53 class mediator | 92/5968 | 163/18723 | 7.29e-11 | 2.54e-09 | 92 |
| GO:1901796113 | Thyroid | PTC | regulation of signal transduction by p53 class mediator | 58/5968 | 93/18723 | 1.38e-09 | 3.95e-08 | 58 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |